- Trilaciclib, sold
under the
brand name
Cosela, is a
medication used to
reduce the
frequency of chemotherapy-induced bone
marrow suppression. The most common...
- with less dose-limiting neutropenia.
Cosela: On
February 12, 2021, the FDA
approved trilaciclib (brand name
Cosela) as a
treatment to
reduce the frequency...
- and G1
Therapeutics announced a co-promotion
agreement for
trilaciclib (
Cosela), a CDK4/6
inhibitor designed to
prevent chemotherapy-induced myelosuppression...
-
treatment of chemotherapy-induced myelosuppression/Neutropenia.
Trilaciclib (
COSELA), a CDK4/6 inhibitor, is
administered before chemotherapy in
small cell...
-
Powell K,
Prasad V (November 2021). "Concerning FDA
approval of
trilaciclib (
Cosela) in extensive-stage small-cell lung cancer".
Transl Oncol. 14 (11): 101206...
- 15, 2021. On
February 12, 2021, the FDA
approved trilaciclib (brand name
Cosela) as a
treatment to
reduce the
frequency of chemotherapy-induced myelosuppression...
-
mediating chemotherapy-induced side effects.
Trilaciclib (V03AF12,
trade name
Cosela) was
approved in
February 2021 to
reduce chemotherapy-induced myelosuppression...
- the
United States Capitol. The U.S. Food and Drug
Administration approves Cosela as the
first therapy in its
class to
reduce the
frequency of chemotherapy-induced...
